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The objective of the trial is to evaluate the efficacy of capecitabine in patients with metastatic hormone-resistant prostate carcinoma
(HRPC), in terms of prostate-specific antigen (PSA) response and clinical benefit (decrease of pain or analgesic score) and its safety
profile. In all, 25 patients with HRPC were enrolled on a phase II trial of capecitabine (Xeloda
s) at a dose of 1250mgm
 2 orally
twice daily on days 1–14 every 21 days. The inclusion criteria were PSA serum levels 43  upper limit of normal, a WHO
performance status 0–2, age o85 years and adequate bone marrow, liver and renal function. In patients with grade 2 or higher
haematological toxicity on day 1 of the treatment cycle, therapy was first delayed, and then continued at a lower dose. Trial end
points were PSA response and clinical benefit defined by quality of life (QL) data and analgesic consumption. The median age of
patients was 70 years (range 54–85 years). A median of three cycles of capecitabine was administered (range 1–8). PSA response
was observed in three patients (12%, 95% CI 3–31%), with times to tumour progression of 18, 21 and 35 weeks, respectively. In
these patients, the response durations were 12, 17 and 32 weeks, respectively. Minor PSA regression was also seen in two further
patients. The median time to tumour progression of all patients was 12 weeks (95% CI 9–15 weeks). Haematological toxicity was
minor, with leukopenia grade 3 observed in one patient. There were three deaths during trial treatment, respectively, due to sepsis
following mucositis and leukopenia, presumed sepsis with mucositis induced by chemotherapy and concomitant radiotherapy and
cerebral dysfunction progressing to coma. Hand–foot syndrome grades 2 and 3 were observed in four patients each. Clinical benefit
was observed in five patients (20%, CI 7–41%). Based on toxicity data, we recommend a lower starting dose of 1000mgm
 2 orally
twice daily. While capecitabine has some activity in HRPC, as suggested by observed PSA responses, we conclude that it is not
worthwhile to investigate capecitabine monotherapy in a phase III trial. Combinations of capecitabine with other agents, such as
vinorelbine or docetaxel, may prove to be more effective.
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The role of chemotherapy in patients with hormone-resistant
prostate cancer (HRPC) has been re-evaluated in recent years
(Goodin et al, 2002). The median survival of patients with HRPC
remains, however, at 9–12 months despite medical advances and
new approaches. Chemotherapy in patients with HRPC has been
shown to decrease the serum levels of prostate-specific antigen
(PSA), to shrink soft tissue metastases, to improve bone scans and,
most importantly, to enhance aspects of quality of life (QL),
especially pain (Tannock et al, 1996; Fields-Jones et al, 1999).
Prolongation of survival by chemotherapy, however, has not been
demonstrated in phase III trials conducted to date (Tannock et al,
1996; Hudes et al, 1999; Kantoff et al, 1999), although adequately
powered randomised trials are now underway comparing mitox-
antrone/prednisone with newer treatments including docetaxel
alone or in combination with estramustine.
Starting in 1991, the Swiss Group for Clinical Cancer Research
(SAKK) conducted four consecutive phase II trials within the
framework of a master protocol to evaluate carboplatin (Jungi et al,
1998), idarubicin (Schmid et al, 1997), gemcitabine (Morant et al,
2000) and vinorelbine (Morant et al, 2002b), in patients with
HRPC. The goal of these studies was to find promising new drugs
for further testing in phase III trials. These multicentre trials
included similar end points, but during the trials requirements
with respect to documentation of response, toxicity, QL and PSA
measurements (Schmid et al, 2003) have evolved.
The fifth substance to be tested as a part of this programme was
capecitabine (Xeloda
s), an oral fluoropyrimidine carbamate that
delivers 5-FU predominantly to tumour cells. Capecitabine is
rapidly and extensively absorbed through the gut as an intact
molecule, and is then metabolised to 5-FU in three steps (Budman
et al, 1998; Miwa et al, 1998; Schu ¨ller et al, 2000). Firstly, it is
converted to 50-deoxy-5-fluorocytidine (50-DFCR) by carboxyles-
terase (primarily in the liver). Secondly, it is converted to 50-deoxy-
5-fluorouridine (50-DFUR) by cytidine deaminase (in tumour cells
and in the liver). Finally, it is converted to 5-FU by thymidine
phosphorylase (TP), which is significantly more active in tumour
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ltissue than in adjacent healthy tissue (Ishikawa et al, 1998). The
increasing specificity for tumour cells occurring with each
successive conversion step potentially reduces systemic 5-FU
exposure while increasing the 5-FU dose within tumour tissue.
Capecitabine is currently approved in over 80 countries
worldwide (including Japan, the USA and EU) as monotherapy
for the treatment of advanced or metastatic breast cancer patients
who have failed previous anthracycline and taxane chemotherapy.
In addition, the combination of capecitabine and docetaxel is
approved for the treatment of patients with advanced or metastatic
breast cancer after failure of cytotoxic chemotherapy including an
anthracycline (or when further anthracycline therapy is not
possible). Capecitabine is also approved for the first-line treatment
of patients with metastatic colorectal cancer.
The objective of the present trial was to evaluate both the
efficacy, in terms of PSA response and clinical benefit, and the
safety profile of capecitabine in patients with HRPC. The primary
end point of the trial was PSA response according to the guidelines
by the PSA Working Group (Bubley et al, 1999). Quality of life and
clinical benefit were secondary end points. In the subset of patients
with measurable disease, tumour response following treatment
with capecitabine was also documented according to standard
WHO criteria.
PATIENTS AND METHODS
Between March 2000 and June 2001, 25 patients with histologically
or cytologically proven metastatic prostatic carcinoma, progres-
sing after orchiectomy or medical castration, were enrolled.
Eligibility criteria included an age limit of o85 years, a life
expectancy of 412 weeks, a WHO performance status of 0–2 and
the absence of known brain metastases. No previous cytotoxic
therapy, including estramustine, was allowed. Requirements for
laboratory values included a serum PSA of at least three times the
upper limit of normal (ULN), leucocytes (WBC) X3.5 10
9l
 1 or
granulocytes X2 10
9l
 1, platelets X100 10
9l
 1, haemoglobin
X90gl
 1, serum creatinine p1.5 ULN, bilirubin p1.5 ULN
and SGOT p2.5 ULN. Measurable or nonmeasurable metastatic
disease was allowed. Bone metastases alone were considered to be
nonmeasurable.
Patients received oral capecitabine at a dose of 1250mgm
 2
twice daily for 14 days, repeated every 21 days. Treatment was
stopped after a maximum of eight cycles or in the event of tumour
progression or severe toxicity. Toxicity was assessed according to
the National Cancer Institute of Canada Common Toxicity Criteria
(NCIC CTC) and a special toxicity scale for severity of skin
toxicity, especially of palms and plants (hand–foot syndrome).
Dose reductions and treatment delays were specified in the
protocol. In an amendment dated March 2001, the initial
capecitabine dose was adapted according to creatinine clearance
values.
The trial had a two-stage Gehan design with a sample size of 25
patients in order to estimate the PSA response rate with a standard
error of o0.10. If capecitabine had a PSA response rate of less than
20%, then the drug would not be considered worth to be tested in a
phase III trial. The trial was designed to be stopped if there were no
PSA responses among the first 14 patients. Since two PSA
responses were seen, the trial continued beyond the initial 14
patients.
Treatment with antiandrogens, however, had to be stopped
at least 1 month before trial enrollment in order not to falsely
attribute an antiandrogen withdrawal response (Scher and Kelly,
1993) to the trial drug. Prior radiation therapy was given to
12 patients. Palliative radiation therapy was not allowed
within 1 month prior to the start of the study treatment.
Previously irradiated metastases were not used for response
evaluation.
The trial was approved by the scientific committee of the SAKK,
the local ethical committees of participating institutions and
regulatory authorities. Written informed consent was obtained
from each patient before entering the trial.
The primary end point of the trial was PSA response (Smith et al,
1998). In addition, clinical benefit, QL data and, if possible, tumour
measurements were recorded.
PSA response was evaluated according to the guidelines for
phase II trials in HRPC (Bubley et al, 1999). The first response
evaluation was performed after two cycles of chemotherapy. A PSA
response is defined as a decrease of serum PSA levels by at least
50% compared to baseline and confirmed by a second determina-
tion 4 weeks later. Moreover, no increase in the size of pre-existing
metastases, no appearance of new lesions and no clinical signs of
tumour progression are allowed. Progressive disease (PD) is
defined as a confirmed increase of PSA values by at least 25%
compared to baseline or nadir levels not reaching response
criteria. Time to PSA progression is defined from the first
treatment day until the date PSA levels had increased by 50%
from the nadir levels for responders or by 25% for patients not
reaching a 50% decline of PSA levels. If clinical progression
occurred before PSA progression, the date of clinical progression
was used. Duration of PSA response is measured from the time at
which PSA had declined to p50% to the time when PSA has risen
by 50% above the nadir. Time to treatment failure was defined as
the time from registration to progression, death or treatment stop
due to toxicity or refusal. Confidence intervals for the Kaplan–
Meier curves were computed on the log survival scale. PSA levels
were determined on day 1 of each treatment cycle.
Pain treatment was not standardised but recorded and classified
by the treating physician at registration, on day 8, at the start of
each treatment cycle and at treatment failure. A pain treatment
score was calculated according to Moore et al (1994) for each visit
by an independent physician. Standard tablets or capsules of non-
narcotic analgesics were assigned 1 point each, and standard doses
of narcotic analgesics (e.g., hydromorphone 2mg, morphine 5mg,
etc.) were assigned two points. These points were totalled for a
daily score and averaged into a score assessing the week before the
clinical visit.
QL was assessed by the EORTC QLQ-C30 (Aaronson et al, 1993)
at registration, on day 8, at monthly visits and at treatment failure.
This questionnaire has extensively been validated in adults,
although not specifically in elderly patients. All scales and single
items were transformed according to the EORTC guidelines to
range from 0 to 100. A higher score for a functional scale
represents a higher level of functioning, a higher score for the
global health status/QL scale a better QL, and a higher score for a
symptom scale or item a higher level of symptoms or problems. In
addition, a global indicator for overall treatment burden (Bernhard
et al, 2002) and another for coping effort (Hurny et al, 1993) were
included. These two indicators were transformed accordingly (0–
100), with higher scores indicating better QL. All questions
referred to the experience during the previous week. Pain (QLQ-
C30 items 9þ19) was prospectively defined as the primary QL end
point, the other measures were used for descriptive purposes only.
Clinical benefit in terms of reduction in patient-rated pain and/
or use of analgesics was defined as either a decrease of X2
response categories (corresponding to X33%) in the pain scale
(items 9þ19) without an increase in analgesics, or a decrease by
X50% in analgesics without an increase in pain, measured from
baseline for at least two consecutive cycles (i.e. 6 weeks).
For the minority of patients who did not report pain at baseline,
we prospectively defined changes in physical functioning and
global health/QL (both from QLQ-C30) as benefit criterion as
either an improvement of X2 response categories (corresponding
to X40%) in physical functioning without any worsening in global
health status/QL, or an improvement of X3 response categories
(corresponding to X25%) in global health status/QL without any
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least two consecutive cycles (i.e., 6 weeks).
We investigated the changes in QL measures from baseline to
subsequent time points. Although the transformation of the QLQ-
C30 scales results in scores ranging from 0 to 100, these measures
are still categorical in nature. Given the small sample, we focused
on median values, instead of means. That is, changes that were
present in means but not in medians (i.e. median¼0) were not
considered relevant. Accordingly, we used the exact Wilcoxon
signed rank test (based on Hodges–Lehmann (HL) medians),
(Lehmann, 1975). All tests were two-sided. No adjustment was
made for multiple testing.
RESULTS
Patient characteristics are shown in Table 1. The 25 men entered
on the trial had a median age of 70 years (range 54–85 years) and
generally had a good performance status (84% having a PS of 0 or
1). All patients had documented PD (rising PSA levels and/or new
or growing metastases) while on continued androgen ablation: 11
patients had undergone bilateral orchiectomy, 13 had received a
luteinising hormone–releasing hormone (LH–RH) agonist, and in
one patient LH–RH agonists were erroneously stopped before trial
enrolment. A total of 15 patients had been treated during the
course of their disease with an androgen receptor blocker either
concomitantly or as a second-line hormonal therapy.
Nearly all patients suffered from bone metastases (24 out of 25).
In nine patients lymph node metastases were found, in two
patients liver metastases and in two lung metastases.
The median number of capecitabine cycles was 3 (range 1–8).
The median dose density of capecitabine dropped from
2471mgm
 2 during cycle 1 (n¼25) to 1875mgm
 2 during cycle
4( n¼11). Dose reductions were necessary in 10 patients, due to
hand–foot syndrome (n¼3), diarrhoea (n¼2), and in one patient
each due to haematological reasons, weight loss, moderate renal
function impairment, vomiting and symptoms of vertebral fracture
with spinal cord compression (the latter were signs of tumour
progression).
Treatment with capecitabine was subjectively well tolerated in
the vast majority of patients. The most common clinical treatment-
related adverse events (grade 2, 3 or 4, see Table 2) were nausea
(32%), hand–foot syndrome (32%) and diarrhoea (16%). Anaemia
was the most commonly observed haematological toxicity (40%),
although the majority of cases (36%) were no greater than grade 2
in severity. Other grade 2/3 haematological adverse events were
granulocytopenia (12%), leukopenia (12%) and thrombocytopenia
(8%), although no grade 4 haematological toxicity was noticed.
Three patients died during the trial: one patient developed
mucositis during the first course of chemotherapy and underwent
radiation therapy involving the already inflamed oral mucosa. The
event was classified as probably related to trial treatment. The
patient was admitted to a regional hospital with sepsis, suspected
to be related to the injured oropharyngeal mucosa. No agranulo-
cytosis was found. The patient’s clinical condition rapidly
deteriorated and he died due to a presumed septic shock.
The second patient died during the second course after
somnolence progressed into coma with a clinical diagnosis of
brain metastases or cerebral infarction. Due to the poor clinical
status at hospital admission, no further work-up had been done.
The third patient died during the first course due to treatment-
related toxicity. This 60-year-old obese patient with extensive
osseous and hepatic metastases was treated with 5g of capecitabine
daily. He developed mucositis and diarrhoea and was then
admitted to the hospital 10 days after starting chemotherapy.
Administration of capecitabine was stopped. He was neutropenic
and was treated with antibiotics. He succumbed to infection on the
tenth day of hospitalisation.
The median time to tumour progression of the 21 patients
completing at least two cycles was 12 weeks (95% CI 9–15 weeks,
Figure 1) and median time to treatment failure of all the 25 patients
was 9 weeks (95% CI 7–15 weeks, Figure 2). Treatment failure was
recorded in 20 patients as a result of PD (clinical tumour
progression in eight cases, PSA progression in 12 cases), in three
patients because of death and in one patient each by patient refusal
and unacceptable toxicity.
PSA levels of all trial patients before and during treatment with
capecitabine are plotted in Figure 3. A PSA response according to
standardised criteria was seen in three patients (12%, 95% CI 3–
31%). Response durations and times to tumour progression in
these patients were 12, 17 and 32 weeks and 18, 21 and 35 weeks,
Table 1 Patient characteristics (n¼25)
Category Number %
Performance status (WHO) 0 8 32
11 3 5 2
24 1 6
Previous radiation therapy No 13 52
Yes 12 48
Orchiectomy No 14 56
Yes 11 44
LH-RH analogues No 12 48
Yes 13 52
Antiandrogens No 10 40
Yes 15 60
Measurable disease No 13 52
Yes 12 48
Tumor metastases
a Bone 24 96
Lymph nodes 9 36
Lung 2 8
Liver 2 8
Median Range
Age (years) 70 54–85
Weight (kg) 80 55–113
Disease duration since diagnosis (years) 3 0.55–17.9
PSA (mg/l) 258 15–20400
Alkaline phosphatase (IU) 325 87–1580
Creatinine (mmol) 97 58–155
aEach patient may have more than one tumour localisation.
Table 2 Grade 2, 3 and 4 adverse events following treatment with
capecitabine in 25 patients and 88 treatment cycles
Toxicity Grade
Number
of cycles
(% of cycles)
Number of
patients
(% of patients)
Anaemia 2 17 (19%) 9 (36%)
3 1 (1%) 1 (4%)
Leukopenia 2 4 (5%) 2 (8%)
3 1 (1%) 1 (4%)
Granulocytopenia 2 1 (1%) 1 (4%)
3 2 (2%) 2 (8%)
Thrombocytopenia 2 2 (2%) 2 (8%)
Diarrhoea 2 4 (5%) 3 (12%)
3 1 (1%) 1 (4%)
Neurological 2 4 (5%) 3 (12%)
Nausea 2 10 (11%) 6 (24%)
3 2 (2%) 2 (8%)
Stomatitis 2 1 (1%) 1 (4%)
4 1 (1%) 1 (4%)
Hand–foot syndrome 2 9 (10%) 4 (16%)
3 5 (6%) 4 (16%)
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lrespectively. Minor reductions in PSA (38 and 41%) were seen in
two additional patients. There were no objective tumour responses
of measurable disease.
Of all 113 expected pre-failure QL forms, 99 (88%) were received
and correctly timed, 24 (96%) at baseline and 75 (85%) during
treatment; the submission rate at failure was lower (73%). The
reasons for missing QL data were mainly local administrative
failure (45%); in 40% of all missing data, there was no reason
given. QL data were evaluated up to the beginning of cycle 4;
thereafter, too few patients were left on the trial treatment.
At baseline, patients reported a considerably impaired health
status/QL (n¼24, median¼50), role functioning (n¼23, med-
ian¼66.7), coping (n¼24, median¼58.3) and emotional func-
tioning (n¼24, median¼75). Pain was the most severe symptom
(n¼23, median¼50), followed by fatigue (n¼24, median¼33.3)
and sleeping disorders (n¼24, median¼33.3).
At day 8 of the first capecitabine cycle, short-term toxicity did
not result in worsening in any of the QL measures. Patients
reported better emotional functioning (n¼17, HL median
change¼12.5, P¼0.003) and coping (n¼18, HL median
change¼8.3, P¼0.02), and less pain (n¼17, HL median
change¼ 16.7, P¼0.02) and sleeping disorders (n¼18, HL
median change¼ 16.7, P¼0.05). Besides this early improvement,
there was no substantial change over the observation period (up to
the beginning of cycle 4).
Physician-rated pain indicated deterioration at the beginning of
cycles 3 (n¼16, median change¼ 1, P¼0.04) and 4 (n¼9,
median change¼ 1, P¼0.03), when compared to baseline
(n¼25, median¼2). The pain treatment score indicated a stable
consumption of analgesics (baseline: n¼24, median¼4.6).
In all, 22 patients reported pain at baseline. Five of these (20%)
met our criteria for clinical benefit following treatment with
capecitabine, and in one case clinical benefit could not be
evaluated because of missing data. For at least two consecutive
cycles, these patients indicated either a decrease of X2 response
categories in the pain scale from baseline without an increase in
analgesics, or a decrease by X50% in analgesics without an
increase in pain. One of these patients had also a PSA response.
The two cases without baseline pain did not meet our criteria for
palliation based on physical functioning and global health/QL.
DISCUSSION
The SAKK has performed five consecutive phase II trials in
patients with HRPC, the latest using capecitabine.
Capecitabine has demonstrated consistently high single-agent
activity and a favourable safety profile in taxane and anthracycline
Time to progression
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Figure 1 Time to first progression (prostate-specific antigen (PSA) or
clinical) measured in weeks with pointwise 95% confidence intervals.
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Figure 2 Time to treatment failure (tumour progression, toxicity, death,
refusal) in weeks with pointwise 95% confidence intervals.
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Figure 3 PSA values (A) before and (B) after trial registration, that is,
start of chemotherapy. Each line represents the PSA profile of one patient.
The slope of rising PSA levels is less steep after the start of chemotherapy.
The dashed lines represent the three cases with a PSA response.
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lpretreated metastatic breast cancer (Blum et al, 1999, 2001;
Fumoleau et al, 2001; Talbot et al, 2002) and improved overall
survival when added to docetaxel in the anthracycline-failure
setting (O’Shaughnessy et al, 2002). In addition, randomised phase
III trials comparing the efficacy and tolerability of 3-weekly
intermittent capecitabine with i.v. bolus 5-FU/LV as first-line
treatment of advanced colorectal cancer showed that capecitabine
was more active than 5-FU/LV in the induction of tumour
response, and at least equivalent in terms of time to progression
and overall survival (Hoff et al, 2001; Van Cutsem et al, 2001;
Twelves, 2002). In addition to the extensive experience with
capecitabine in patients with breast and colorectal cancer, the drug
has been investigated in a variety of other cancers, such as
pancreatic carcinoma (Hess et al, 2003), whereas there is only a
single recent case report (El-Rayes et al, 2003) describing an
impressive response to capecitabine in a patient with HRPC.
Experience with 5-FU in patients with HRPC has been mixed
with no responses seen in phase II trials with 5-FU and leucovorin
given as bolus injections (Singh et al, 1992), high dose infusions
every 2 weeks (Atkins et al, 1996) or continuous infusion over 5
days (Kuzel et al, 1993). However, 5-FU given as a continuous
infusion of 300mgm
 2 (Hansen et al, 1991) showed a significant
palliative effect. In prostatic carcinoma, there are significantly
higher levels of TP (Mori et al, 2000), which is likely to result in
higher levels of 5-FU in tumour tissue following administration of
capecitabine. The previous benefit of a continuous low dose
infusion of 5-FU combined with increased drug accumulation in
tumour tissue provided the rationale for this phase II trial.
In this first phase II trial of capecitabine in HRPC, the drug has
demonstrated a confirmed PSA response rate of 12% (three of 25
patients) and a mean response duration of 20 weeks (12, 17 and 32
weeks). In addition, two further minor PSA responses were seen.
Comparison of PSA values before and after the start of
chemotherapy shows that the slope of rising PSA values became
less steep in the majority of patients, even if there were no
responses (Figure 3). This temporary stabilisation of disease
translates into a median time to progression of 12 weeks and a
median time to treatment failure of 9 weeks.
Subjective toxicity of capecitabine was mild in the majority of
the patients. The most common clinical treatment-related adverse
events (grades 2, 3 or 4) were nausea (32%), hand–foot syndrome
(32%) and diarrhoea (16%). Anaemia was the most commonly
observed haematological toxicity (40%), although no grade 4
haematological toxicity was recorded. Diarrhoea and mucositis
were observed in two of the three patients who died during the
trial. Considering the observed toxicity and the frequent dose
reduction, we recommend a lower starting dose of 1000mgm
 2
orally twice daily and to adapt dosages in cases of decreased
creatinine clearance.
These results, although not directly comparable, are not
substantially different from those of many other phase II trials
in HRPC, such as our previous trials with gemcitabine or
vinorelbine. However, they do not match the higher response
rates reported with docetaxel (Picus and Schultz, 1999) alone or in
combinations with estramustine (Petrylak et al, 1999) or other
agents targeting microtubule functions, such as vinblastine (Hudes
et al, 1999).
Overall, the QL results indicate that capecitabine was relatively
well tolerated. In particular, there was no worsening of QL by
short-term toxicity. The improvement in several QL measures over
the first 8 days may reflect the beneficial impact of the pain
treatment and general support given by the treating physician at
baseline, because we do not expect a beneficial effect of
chemotherapy on tumour load at this early time point. However,
considering the whole observation period, there was no overall
improvement in patient- or physician-rated pain. Similarly, the QL
measures did not suggest an overall improvement during
capecitabine treatment. This is an indication of limited palliation
as described in our previous trial of vinorelbine (Morant et al,
2002b), which showed a comparable rate of clinical benefit (23%).
In summary, capecitabine monotherapy has proven to be a
substance with some activity in patients with HRPC and with
generally good tolerability. Careful clinical supervision by an
experienced oncologist is, however, necessary, because potentially
life-threatening complications, such as stomatitis, leukopenia or
diarrhoea may develop, necessitating treatment interruption or
dose reduction.
The activity of capecitabine in this patient population is limited
concerning both PSA response and clinical benefit. Hence,
capecitabine cannot be recommended as a single first-line drug
in patients with metastatic HRPC, and we do not think that it is
worthwhile to investigate capecitabine monotherapy in a phase III
trial. Whether combinations of capecitabine with noncytotoxic
agents or other cytostatic drugs, such as docetaxel or vinorelbine,
which are combination regimens with proven efficacy in breast
carcinoma, will also be useful in this patient population, will
require further investigation.
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